1. Liver-Targeted Gene and Cell Therapies: An Overview.-
Part I. Cell Therapy.-
2. Macrophage Therapy for Liver Fibrosis and Regeneration.-
3. Liver Regeneration Therapy Using Autologous Bone Marrow-Derived Cells for Cirrhotic Patients.-
4. Novel Immunotherapy Using Liver Natural Killer Cells for Preventing Recurrence of Hepatocellular Carcinoma in Liver Transplantation.-
5. Cell-Based Immunotherapy for HCC: Our Experiences and Future Directions.-
Part II. Gene Therapy.-
6. AAV Vector-Mediated Liver Gene Therapy and Its Implementation for Hemophilia.-
7. Potential Usage of Human Artificial Chromosome for Regenerative Medicine.-
8. Image-Guided Hydrodynamic Gene Delivery to the Liver: Toward Clinical Applications.-
Part III. Legal Regulation
9. The Way to Clinical Applications of Human Pluripotent Stem Cells.-
10. Regulation for Gene and Cell Therapy Medicinal Products in Europe.-
11. IPSC-Derived Products: Current Regulations.-
12. Critical Path Initiative for Regenerative Medicine in Japan.-
13. Aseptic Manufacturing of Regenerative Medicine Products Using Isolator Technology.-
14. Cell and Vector Production Facility for Gene Therapy and Cell Therapy.
1. Liver-Targeted Gene and Cell Therapies: An Overview.-
Part I. Cell Therapy.-
2. Macrophage Therapy for Liver Fibrosis and Regeneration.-
3. Liver Regeneration Therapy Using Autologous Bone Marrow-Derived Cells for Cirrhotic Patients.-
4. Novel Immunotherapy Using Liver Natural Killer Cells for Preventing Recurrence of Hepatocellular Carcinoma in Liver Transplantation.-
5. Cell-Based Immunotherapy for HCC: Our Experiences and Future Directions.-
Part II. Gene Therapy.-
6. AAV Vector-Mediated Liver Gene Therapy and Its Implementation for Hemophilia.-
7. Potential Usage of Human Artificial Chromosome for Regenerative Medicine.-
8. Image-Guided Hydrodynamic Gene Delivery to the Liver: Toward Clinical Applications.-
Part III. Legal Regulation
9. The Way to Clinical Applications of Human Pluripotent Stem Cells.-
10. Regulation for Gene and Cell Therapy Medicinal Products in Europe.-
11. IPSC-Derived Products: Current Regulations.-
12. Critical Path Initiative for Regenerative Medicine in Japan.-
13. Aseptic Manufacturing of Regenerative Medicine Products Using Isolator Technology.-
14. Cell and Vector Production Facility for Gene Therapy and Cell Therapy.